MIR155HG^Δexon3 T cells retain beneficial GVL effect. NSG mice were irradiated and injected with GFP⁺ luciferase–transduced FLT3-ITD⁺ MOLM-13 AML cells along with TCD-PBMCs alone (open green circles) or TCD-PBMCs with either NT (filled red circles) or MIR155HG^Δexon3 T cells (filled blue boxes). (A) Whole-body bioluminescent signal intensity of recipient NSG mice (n = 3 or 4) from 1 representative donor. Mice were imaged on indicated days. (B) Survival curve from 2 independent donors (n = 5 or 6). (C-D) Splenocytes were isolated at time of death and (C) MOLM-13 leukemic burden evaluated by GFP positivity and (D) percentage live CD3⁺ T cells were evaluated using flow cytometry (n = 5 or 6 combined) from 2 independent transplants or donors. (E) Percentage IFN-γ and CD107a double-positive CD8⁺ T cells in splenocytes. (F) Representative contour plots of panel E. (G) Fold change in miR-155 expression measured by qRT-PCR at 72 hours (left) and 7 days (right) after transfection of human donors used for GVL transplants (∗P < .05, ∗∗P < .01, ∗∗∗P < .001).